BEI
CORT icon

Benjamin Edwards Inc’s Corcept Therapeutics CORT Stock Holding History

Benjamin Edwards Inc’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-463
Closed -$9K – 703
2021
Q4 		$9K Buy
463
+411
+790% +$8.34K ﹤0.01% 592
2021
Q3 		$1K Buy
+52
New +$1.09K ﹤0.01% 523

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Benjamin Edwards Inc's CORT Position: Q1 2022 in Review

Benjamin Edwards Inc sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 463 shares — an estimated $9K sold.

Benjamin Edwards Inc first reported a position in CORT in Q3 2021 and held it in 2 quarters. The position peaked at $9K in Q4 2021. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • Benjamin Edwards Inc reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Benjamin Edwards Inc sold 463 Corcept Therapeutics shares in Q1 2022, an estimated $9K.
  • Benjamin Edwards Inc first reported a position in Corcept Therapeutics in Q3 2021 and held it in 2 quarters.
  • Benjamin Edwards Inc's Corcept Therapeutics position peaked at $9K in Q4 2021.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on Benjamin Edwards Inc's 13F filing for Q1 2022, filed 4 May 2022.